Technical Analysis for RHHBY - Roche Hldg Ltd Spons

Grade Last Price % Change Price Change
A 47.49 -0.67% -0.3200
RHHBY closed down 0.67 percent on Thursday, June 17, 2021, on 47 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical RHHBY trend table...

Date Alert Name Type % Chg
Slingshot Bullish Bullish Swing Setup 0.00%
Doji - Bullish? Reversal 0.00%
Overbought Stochastic Strength 0.00%
Gapped Down Weakness 0.00%
Golden Cross Bullish -0.67%
New 52 Week Closing High Bullish -0.67%
New 52 Week High Strength -0.67%
Overbought Stochastic Strength -0.67%
Up 3 Days in a Row Strength -0.67%
New 52 Week High Strength -0.59%
Older End-of-Day Signals for RHHBY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Jack-in-the-Box Bullish Entry 8 days ago
Rose Above Previous Day's High 8 days ago
Up 3% 8 days ago
Up 2% 8 days ago
Up 1% 8 days ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Roche Hldg Ltd Spons Description

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Life Sciences Diabetes Pharmaceutical Products Pharmaceutical Industry In China Immunology Infectious Diseases Disease Ophthalmology Neuroscience Molecular Diagnostics Archer Nucleic Acid Gene Expression Sequencing Pega Avast Chugai Pharmaceutical Co. Diabetes Care Hoffmann La Roche Roche Diagnostics Division Genentech Pegasys Pharmaceuticals Division

Is RHHBY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 48.38
52 Week Low 39.72
Average Volume 1,325,018
200-Day Moving Average 42.8953
50-Day Moving Average 43.0870
20-Day Moving Average 45.1400
10-Day Moving Average 46.9780
Average True Range 0.6489
ADX 46.73
+DI 52.9004
-DI 14.8966
Chandelier Exit (Long, 3 ATRs) 46.4333
Chandelier Exit (Short, 3 ATRs) 44.0067
Upper Bollinger Bands 49.1803
Lower Bollinger Band 41.0997
Percent B (%b) 0.79
BandWidth 17.9012
MACD Line 1.4943
MACD Signal Line 1.2565
MACD Histogram 0.2378
Fundamentals Value
Market Cap 324.7 Billion
Num Shares 6.84 Billion
EPS 1.54
Price-to-Earnings (P/E) Ratio 30.93
Price-to-Sales 4.62
Price-to-Book 8.73
PEG Ratio 2.54
Dividend 1.14
Dividend Yield 2.40%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 48.0000
Resistance 3 (R3) 48.0000 47.8300 47.9150
Resistance 2 (R2) 47.8300 47.7001 47.8300 47.8866
Resistance 1 (R1) 47.6600 47.6199 47.5750 47.6600 47.8583
Pivot Point 47.4900 47.4900 47.4475 47.4900 47.4900
Support 1 (S1) 47.3200 47.3601 47.2350 47.3200 47.1217
Support 2 (S2) 47.1500 47.2799 47.1500 47.0934
Support 3 (S3) 46.9800 47.1500 47.0650
Support 4 (S4) 46.9800